SAN DIEGO & MILAN, Italy--(BUSINESS WIRE)--Nov. 2, 2005--Androclus Therapeutics announced the completion of a Phase II clinical trial of AT-001 (dnaJP1), a novel orally administered therapeutic candidate for the treatment of rheumatoid arthritis (RA).